Bioxin Biotech is a returnee start-up company focusing on the discovery and preclinical development of innovative antibody drug molecules. Through the H³ antibody technology platform and the collaborative antibody technology platform, it has developed an innovative antibody drug molecule seed bank. The indications cover malignant tumors, tumor immunity , autoimmune diseases, inflammatory and cardiovascular diseases and other diseases. Bioxin Biotech recently completed its B round of financing exceeding RMB 100 million. This round of financing was led by GF Xinde, followed by Fangsheng Fund, Yida Capital, and Suxin Venture Capital. Dr. Li Chen from GF Xinde will join Bioxin’s board of directors.
This article is transferred from: https://www.itjuzi.com/investevent/13744929
This site is only for collection, and the copyright belongs to the original author.